Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 201 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Clearmind Medicine Inc | CMND | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.21 | 07:59:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.21 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 7 | 201 | - | 0.9205 - 20.40 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:46:50 | formt | 144 | US$ 1.21 | USD |
Clearmind Medicine Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 3.84M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Clearmind Medicine News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CMND Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.27 | 1.37 | 1.17 | 1.24 | 92,150 | -0.06 | -4.72% |
| 1 Month | 1.20 | 1.80 | 1.14 | 1.47 | 2,656,838 | 0.01 | 0.83% |
| 3 Months | 1.74 | 1.80 | 1.05 | 1.44 | 1,075,456 | -0.53 | -30.46% |
| 6 Months | 3.66 | 6.80 | 0.9205 | 2.61 | 1,855,554 | -2.45 | -66.94% |
| 1 Year | 18.039 | 20.40 | 0.9205 | 4.30 | 1,501,105 | -16.83 | -93.29% |
| 3 Years | 162.60 | 183.00 | 0.9205 | 11.23 | 1,302,184 | -161.39 | -99.26% |
| 5 Years | 162.60 | 183.00 | 0.9205 | 11.23 | 1,302,184 | -161.39 | -99.26% |
Clearmind Medicine Description
| Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. |
